JP2023109947A5 - - Google Patents

Download PDF

Info

Publication number
JP2023109947A5
JP2023109947A5 JP2023085969A JP2023085969A JP2023109947A5 JP 2023109947 A5 JP2023109947 A5 JP 2023109947A5 JP 2023085969 A JP2023085969 A JP 2023085969A JP 2023085969 A JP2023085969 A JP 2023085969A JP 2023109947 A5 JP2023109947 A5 JP 2023109947A5
Authority
JP
Japan
Prior art keywords
component
hours
pharmaceutically acceptable
pharmacologically active
active form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023085969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023109947A (ja
JP7594045B2 (ja
Filing date
Publication date
Priority claimed from JP2020015828A external-priority patent/JP6943994B2/ja
Application filed filed Critical
Publication of JP2023109947A publication Critical patent/JP2023109947A/ja
Publication of JP2023109947A5 publication Critical patent/JP2023109947A5/ja
Application granted granted Critical
Publication of JP7594045B2 publication Critical patent/JP7594045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023085969A 2015-01-28 2023-05-25 薬学的組成物 Active JP7594045B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562108616P 2015-01-28 2015-01-28
US62/108,616 2015-01-28
JP2020015828A JP6943994B2 (ja) 2015-01-28 2020-01-31 神経精神系障害の治療のための組成物および方法
JP2021147148A JP7288016B2 (ja) 2015-01-28 2021-09-09 神経精神系障害の治療のための組成物および方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021147148A Division JP7288016B2 (ja) 2015-01-28 2021-09-09 神経精神系障害の治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2023109947A JP2023109947A (ja) 2023-08-08
JP2023109947A5 true JP2023109947A5 (https=) 2023-10-19
JP7594045B2 JP7594045B2 (ja) 2024-12-03

Family

ID=56544502

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017540782A Active JP6655090B2 (ja) 2015-01-28 2016-01-28 神経精神系障害の治療のための組成物および方法
JP2020015828A Active JP6943994B2 (ja) 2015-01-28 2020-01-31 神経精神系障害の治療のための組成物および方法
JP2021147148A Active JP7288016B2 (ja) 2015-01-28 2021-09-09 神経精神系障害の治療のための組成物および方法
JP2023085969A Active JP7594045B2 (ja) 2015-01-28 2023-05-25 薬学的組成物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2017540782A Active JP6655090B2 (ja) 2015-01-28 2016-01-28 神経精神系障害の治療のための組成物および方法
JP2020015828A Active JP6943994B2 (ja) 2015-01-28 2020-01-31 神経精神系障害の治療のための組成物および方法
JP2021147148A Active JP7288016B2 (ja) 2015-01-28 2021-09-09 神経精神系障害の治療のための組成物および方法

Country Status (8)

Country Link
US (4) US20170326127A1 (https=)
EP (2) EP4385575A3 (https=)
JP (4) JP6655090B2 (https=)
KR (6) KR20220071297A (https=)
CN (2) CN107206093A (https=)
DK (1) DK3251699T3 (https=)
ES (1) ES2985064T3 (https=)
WO (1) WO2016122218A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110719778B (zh) * 2017-04-24 2024-06-18 才思治疗公司 用于治疗抑郁的组合物和方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
KR102176538B1 (ko) 2019-01-31 2020-11-09 한국과학기술연구원 항정신병성 약물 검출용 fret 바이오센서 및 이를 이용한 검출 방법
EP4301464A1 (en) * 2021-03-06 2024-01-10 Universitätsspital Basel Using geno- or phenotyping to adjust lsd dosing
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
JP7846211B2 (ja) 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス, インコーポレイテッド 治療適用のためのd-リゼルグ酸ジエチルアミドの即時放出製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
WO1997003671A1 (en) * 1995-07-14 1997-02-06 Medeva Europe Limited Composition comprising d-threo-methylphenidate and another drug
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
AU2002348135A1 (en) * 2001-10-31 2003-05-12 Recovery Pharmaceuticals, Inc. Methods for the treatment of addiction
PT1587789E (pt) 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
CN101132777A (zh) * 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
US7686560B2 (en) * 2005-12-08 2010-03-30 Conestoga Cold Storage Rack, conveyor and shuttle automated pick system
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド 5ht受容体介在性の神経新生
EP3085231A1 (en) * 2008-05-27 2016-10-26 Intra-Cellular Therapies, Inc. Method and compositions for sleep disorders and other disorders
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders

Similar Documents

Publication Publication Date Title
JP2023109947A5 (https=)
JP6062465B2 (ja) カルビドパ/レボドパ胃内滞留性薬物供給
US4309405A (en) Sustained release pharmaceutical compositions
JP2024113000A (ja) Hiv予防のためのカプシド阻害剤
CN110051638B (zh) 包含双胍的延迟释放组合物
TWI468191B (zh) 有機化合物之調配物
TR201900067T4 (tr) Ketiyapinin yağ asidi konjugatları, bunların yapılmasına ve kullanılmasına yönelik proses.
CN110693867A (zh) 用于治疗代谢性病症的组合物和方法
RU2010135831A (ru) Способы, лекарственные формы и наборы для введения зипрасидона без пищи
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
CN107205969B (zh) 糖尿病治疗用药物组合物
AU2014299447B2 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
CN104780915A (zh) 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
JP2024522817A (ja) フェニルピロールアミノグアニジン塩及び製剤
CN120112279A (zh) 药物制剂及其用途
JP5678088B2 (ja) 4−メチルピラゾール製剤
WO2021074284A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
RU2018104691A (ru) Композиции с модифицированным высвобождением ницерголина
JP7801408B2 (ja) レボケトコナゾールによる疾患の処置方法
JP2021530568A5 (https=)
JP2022540917A5 (https=)
JP2022500351A5 (https=)
JP2009507850A5 (https=)
JP2024084670A5 (https=)
CN118922214A (zh) Ntsr1靶向放射性药物及检查点抑制剂的组合疗法